Novartis will receive $750m in milestone payments linked to Xiidra, SAF312 (libvatrep) and OJL332 sales. Credit: Novartis AG.

Novartis has entered an agreement to divest its ophthalmology assets to eye health firm Bausch + Lomb in a deal valued at $2.5bn.

The divested products comprise Xiidra, SAF312 (libvatrep) and OJL332. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Xiidra is an approved prescription therapy indicated for treating dry eye disease.

SAF312 is an investigational asset being developed as a chronic ocular surface pain treatment. 

A second-generation TRPV1 antagonist, OJL332 is currently in the pre-clinical development stage.

The agreement also comprises the usage rights for the AcuStream delivery device in dry eye disease indications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The deal comprises an upfront payment of $1.75bn in cash to Novartis, which will also receive $750m in future milestone payments linked to Xiidra, SAF312 (libvatrep) and OJL332 sales.

To guarantee a constant supply of Xiidra to patients, Novartis will continue distributing the therapy on behalf of Bausch + Lomb under transitional agreements following closure of the deal.

The divestiture will conclude in the second half of 2023.

Novartis chief strategy and growth officer Ronny Gal stated: “This transaction will enhance our focus on prioritised innovative medicines to alleviate society’s greatest disease burdens, achieve the greatest patient impact and drive our growth strategy.

“Our ongoing portfolio refinement enables us to best deploy our scientific expertise and resources towards priority programmes and therapeutic areas, while remaining open to opportunistic development for additional high-impact conditions leveraging our advanced technology platforms.”

In June 2023, Novartis agreed to acquire US-based clinical-stage biopharmaceutical firm Chinook Therapeutics in a $3.5bn deal.